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Abstract Current methods of determining the proportion
of people who benefit from a preventive intervention and
the years of life gained can underestimate the former and
overestimate the latter. We describe how to overcome these
errors, using two examples relating to the prevention of
myocardial infarction (MI) and stroke, one using a speci-
fied polypill daily from age 50 and another reducing salt
intake in the population. Standard life table analysis was
used to calculate the person-years of life gained without an
MI or stroke, based on estimates of the incidence of these
disorders in England and Wales. The proportion of indi-
viduals who benefit was taken as everyone who would,
without treatment, have an MI or stroke (holistic model),
rather than limiting the benefit to the proportion calculated
from the relative risk reduction (reductionist model), as is
current practice. Under the holistic model, 33 % of people
who take the polypill from age 50 benefit, gaining, on
average, 8 years of life without an MI or stroke (19 % and
14 years under the reductionist model). Estimates for
reducing salt intake by 6 g/day are 33 % and 2.8 years
respectively under the holistic model (6 % and 16 years
under the reductionist model). In the prevention of disor-
ders such as stroke by reducing exposure to causal factors
such as blood pressure, the use of a holistic model corrects
the underestimation of the proportion of people who benefit
and the overestimation of their years of life gained asso-
ciated with current methods.
Keywords Relative risk reduction  Absolute risk
reduction  Health benefits  Polypill  Statins  Blood
pressure lowering drugs  Salt intake reduction
Introduction
In spite of many publications on the effects of interventions
to prevent chronic diseases, there is no satisfactory method
of accurately estimating and expressing the resulting health
benefits. The benefits are often presented as the relative and
absolute risk reductions, but these two measures can give
contradictory impressions of the size of the benefit. For
example, a preventive intervention that reduces the risk of
a disease by 70 % confers an absolute risk reduction of
only 0.7 % a year if the prevalence of the disease without
treatment were 1 %. The absolute risk reduction takes
account of the background incidence but estimates vary
according to the place, time, and the time interval over
which the risk reduction is considered (e.g. per year, per
10 years, etc.), and for disorders that become more com-
mon with increasing age, the estimates will not be a simple
multiple of the time interval.
The difficulties can be overcome by using standard life
table methods to estimate the person-years of life gained
without the clinical events health interventions are
designed to prevent (see for example Franco et al. [1]). But
there remains a problem in using such estimates to deter-
mine the proportion of people who benefit, and among
these an estimate of the average years of life gained.
The standard method of calculating these two measures
of benefit, which is appropriate when the preventive effect
benefits only a proportion of people who would, in the
absence of intervention, have been affected, is to use the
relative risk reduction to separate, into two groups, the
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number of people who would have had a clinical event that
the intervention is designed to prevent: one that experi-
ences all the benefit, and another that experiences no
benefit. For example, if, in 1,000 people, ten would have a
clinical event in the absence of treatment, and the pre-
ventive treatment reduces risk by 50 %, the benefit is taken
to be limited to five of the ten, while the other five have no
benefit at all. This model (which we refer to as the
reductionist model) is sometimes appropriate, for example,
with the use of folic acid supplements before and during
early pregnancy to prevent a neural tube defect. In this
example the only babies who benefit are those in whom the
defect was prevented. Not all babies who would have had a
neural tube defect in the absence of taking a folic acid
supplement benefit; those who have such a defect in spite
of taking supplements receive no benefit.
The standard method that uses the reductionist model is,
however, not appropriate for the prevention of a chronic
disease, such as ischaemic heart disease, in which clinical
events arise from the disease over time, and the preventive
effect is expected to benefit everyone who would, in the
absence of intervention, have been affected. In these cir-
cumstances the incidence of clinical events arising from the
disease is reduced by reducing exposure to the causes of
the disease. In expectation, the clinical events will be
delayed in everyone who would have had an ischaemic
heart disease event when not taking preventive treatment,
some for short periods and others by longer. The benefit
will not be restricted to those for whom the ischaemic heart
disease event was completely prevented; it will also extend
to those for whom the event was delayed. In our example
above, in which ten people have a clinical event in the
absence of treatment, in expectation, all ten would benefit
by having their clinical event delayed as well as prevented
altogether. This implies a different model, which we pro-
pose here and refer to as the holistic model. The total
person-years of life gained is the same for both models, say
100; in the holistic model each person who benefits gains
10 years on average (100/10) but in the reductionist model
it is 20 (100/5).
We here use two examples to illustrate the application of
the holistic model in determining health benefits: (1) the
prevention of myocardial infarction and stroke through
taking a combination of blood pressure lowering drugs and
a statin (polypill), and (2) the prevention of these disorders
through reducing daily salt intake.
Methods
Standard life table methods were used to estimate two speci-
fied health benefits, namely (1) the proportion of individuals
who adopt a preventive intervention who will directly benefit
from the intervention (Health Benefitproportion; HBp) over their
lifetime (up to age 99 or prior death), and among these (2) the
average years of life gained without the disorder or disorders
that the intervention is designed to prevent (Health Bene-
fitaverage gain; HBag). At the end of each year of age a person
could be: (1) alive without the specified disorder, or (2) alive
or dead with the specified disorder, or (3) dead without the
specified disorder. This takes into account so called ‘‘com-
peting’’ causes of death. Over time, individuals can move from
1 to 2 or from 1 to 3, but not from 2 to 3, 2 to 1, nor 3 to 1.
Separate sex specific life tables were constructed for people
who do not receive the preventive intervention and for those
who do.
For people who do not have the preventive intervention,
the probability of moving from state 1 to 2 was the age-sex
specific annual incidence of the first occurrence of the
specified disorder (see ‘‘Appendix’’ for details), and the
probability of moving from state 1 to 3 was the age-sex
specific annual mortality from all causes, excluding the
specified disorder [2].
For people who do have the preventive intervention, the
probability of moving from state 1 to state 2 was the age-
sex specific annual incidence of the first occurrence of the
specified disorder multiplied by the age-sex specific rela-
tive risk reductions arising from the preventive interven-
tion, and the probability of moving from state 1 to 3 was
the same as for people who did not have the intervention.
Under the holistic model the number of people who
benefit is all those who had the specified disorder in the no
intervention group. Under the reductionist model only a
proportion benefit, that proportion being the estimate of the
relative risk reduction. Numerically, this is equivalent to
the number of people who benefit, taken as those who have
the specified disorder in the no intervention group minus
those who have the specified disorder in the intervention
group. Their average gain in disorder-free life is the total
disorder-free years of life gained, divided by the number of
people who benefit under each model. No discounting of
the gain was adopted because in policy terms a year of life
gained in people of a given age now should not be assigned
a greater value than one in people of the same age in the
future [3]. Also, the use of quality adjusted life years
(QUALYs) gained does not arise because we consider
years gained without a clinical event that the intervention is
designed to prevent.
Figure 1 illustrates the difference between the holistic
and reductionist models. The figure shows two hypothetical
individuals (A and B) aged 50 who, without treatment,
have a myocardial infarction at age 55, but on treatment
this would have been delayed by 10 years. Individual A has
a myocardial infarction aged 65, and Individual B dies of
cancer at age 60. Under the holistic model both individuals
benefit because both gain extra years of life without a
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myocardial infarction or stroke. A gains 10 years but B
gains only 5 years. Under the reductionist model A does
not benefit because he has a myocardial infarction, albeit
10 years later than would otherwise be the case, but B does
benefit even though the benefit is less, due to the inter-
current death from cancer. The years of life gained for A
and B together is 15, so under the reductionist model the
average is 15 years (15/1) while under the holistic model it
is 7.5 years (15/2). The reductionist model systematically
underestimates the proportion of people who benefit and
overestimates the years of life they gain.
We applied the holistic model to two different inter-
ventions, both designed to prevent a first myocardial
infarction or stroke, and compared the results with those
obtained using the reductionist model. We did not perform
an economic analysis because the purpose of our paper was
limited to assessing health benefits. The two interventions
were: (1) use of a daily four component polypill consisting
of amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide
12.5 mg, and simvastatin 20 mg taken from ages 50, 60, 70
or 80 and (2) daily salt intake reductions of 1.5, 3, 4.5 and
6.0 g. We used these two examples because their effects
are well documented quantitatively, and because of their
potential in preventing cardiovascular disease [4–8]. We
also considered the blood pressure drugs used alone, the
statin alone, and both the salt reduction and polypill used
together. The appendix gives further details specific to
these examples.
Statistical analyses were performed using the R statis-
tical package.
Results
Table 1 shows estimates of the two specified health bene-
fits (HBp and HBag) using the holistic model, according to
the age at which people start to take the polypill. The table
also shows the relative and absolute risk reductions. The
relative risk reduction is 56 % in people starting treatment
at age 50, and the absolute annual risk reduction is 0.37 %.
An estimated 33 % of people taking the preventive treat-
ment benefit (HBp), and these gain, on average, 8.0 years
of life without a myocardial infarction or stroke (HBag).
The remaining 67 % do not benefit, because they die from
another disorder before they would have had a myocardial
infarction or stroke.
Table 1 shows that the specified health benefits diminish
with increasing age of starting the polypill, both in respect of
the percentage who benefit and the average years of life
gained, although the effect on the percentage who benefit is
modest. For example, at age 50 the percentage who benefit is
33 % compared with 29 % for those who start at age 80, and
the years of life gained reduce from 8.0 to 3.4, respectively.
Table 2 shows estimates of the health benefits among
individuals aged 50 or older according to the level of salt
intake reduction. If salt intake is reduced by 6 g/day, 33 %
of individuals benefit (HBp) and they gain, on average,
2.8 years without a myocardial infarction or stroke (HBag).
Table 3 compares the two specified health benefit
measures among people aged 50 and over for different
preventive strategies. The proportions of people who ben-
efit are the same (33 %), but the years of life gained
without a myocardial infarction or stroke varies from 2.8 to
8.8 years.
Discussion
Specifying both the percentage of people who benefit from
a health intervention (HBp) and, among these, the average
years of life gained without the disorder in question
(myocardial infarction and stroke in our examples) is a
Fig. 1 Illustration of the effect
of intercurrent death on the
classification of benefit under
the reductionist and holistic
models (MI myocardial
infarction)
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simple, informative way of expressing benefits in pre-
ventive medicine. Our analysis shows the importance of
determining whether a holistic or reductionist model is
used to calculate these estimates.
The holistic model is appropriate when the preventive
measures exhibit a continuous biological action, such as
blood pressure reduction, in which everyone experiences a
reduction and the health benefits are expected to accrue to
everyone who would have had an event in the absence of
preventive intervention by delaying the event as well as
possibly avoiding it. Had the reductionist model been used,
only an estimated 19 % (33 % minus 15 % from Table 1)
of people aged 50 or over would benefit, but they would
gain, on average, more years of event-free life—14 years
instead of 8.0.
With a 6 g/day reduction in salt intake, using the holistic
model estimates showed that 33 % of people benefit and
gain an average of 2.8 years of life without a myocardial
infarction or stroke. The corresponding figures using the
reductionist model are 6 % and 16 years respectively.
Risk of a myocardial infarction or stroke is currently
often estimated in terms of the probability that a person will
develop a clinical event over the next 10 years, and a risk
‘‘threshold’’ (say a 20 % 10-year risk) is used to identify
people for preventive treatment [9]. Giving a risk estimate
for ‘‘the next 10 years’’ for a preventive treatment that is
intended to be taken indefinitely will underestimate both the
risk and the potential benefit, as most of the preventable
events will arise after 10 years. We therefore used lifetime
benefit, in which the relative risk reduction decreases with
age and the absolute risk reduction increases. For example,
the relative risk reduction from age 50–59 is 81 % (see
Table 6 in the Appendix), and the absolute annual risk
reduction is 0.21 % over this ten year period. At age 80–89
Table 3 The two measures of health benefit in people aged 50 and over according to different preventive interventions to reduce the risk of a






20 mg daily from
age 50
Taking 3 blood pressure
lowering drugs at half standard
dose daily from age 50
Taking polypill
daily from age 50
(all 4 drugs)
Reducing salt by 6 g/day




33 % 33 % 33 % 33 % 33 %
Among these: average years
of life gained without an
MI or stroke (HBag)
2.8 3.9 5.4 8.0 8.8






Proportion of people who
will have first MI or stroke
in the absence of treatment
(%)
Proportion of people who















Among those who benefit :
average years of life gained
without an MI or stroke
(HBag)
50 33 15 56 0.37 33 8.0
60 33 15 55 0.45 33 6.7
70 31 15 53 0.55 31 5.1
80 29 14 51 0.74 29 3.4
Table 2 Estimates relating to the prevention of a first myocardial infarction (MI) or stroke in individuals aged 50 and above according to




who will have first MI
or stroke in the absence
of treatment (%)
Proportion of people
who will have first MI or












of life gained without an
MI or stroke (HBag)
1.5 33 32 4 0.03 33 0.7
3.0 33 30 9 0.06 33 1.5
4.5 33 29 13 0.09 33 2.1
6.0 33 28 17 0.11 33 2.8
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the relative risk reduction is 55 % and the corresponding
absolute annual risk reduction is 1.0 %. Another problem
with using risk to prompt intervention is that it is the size of
the health benefit of the proposed treatment that is relevant,
rather than the risk itself. It is the translation of the reduc-
tion in incidence rates into extended years of life that is
important. Identifying a high risk group without an effective
treatment is pointless. It is the final benefit that needs to be
the basis for decision making, and the estimate of health
benefit should be life-long, not time limited.
Regardless of whether, in a particular context, the reduc-
tionist or holistic model is appropriate, the two specified
measures of health benefit overcome limitations associated
with the use of relative and absolute risk reduction, but the
latter are still needed to calculate the two specified measures of
health benefit. Our estimate of the benefit is robust for two
reasons. First the estimates of relative risk reduction come
from the results of large cohort studies and many randomized
trials that show considerable consistency between studies.
Second, sensitivity analyses showed that estimation of the
specified health benefits were robust to small changes in the
estimates of relative risk reduction, with an approximate
proportional relationship between relative risk reduction and
years of life gained without a myocardial infarction or stroke.
So, for example, a 5 % change in the relative risk reduction
would result in about a 5 % change in years of life gained.
Sensitivity analyses also showed that changes in the inci-
dences of the disorders in question affect the percentage of
people who benefit from preventive interventions to an
approximately proportionate extent, so that, for example,
doubling the incidence in our examples increases the pro-
portion of people who benefit from 33 to 50 %, or from 1:2 to
2:2. However, among those who benefit, the gain in life
without the specified disorders remains similar.
Sometimes the benefit from a health intervention is
expressed as the number needed to treat (NNT), which is the
inverse of the absolute risk reduction. The NNT defined in this
way is valid under the reductionist model, but not under the
holistic model. The benefit from a health intervention is also
sometimes expressed as the years of life gained divided by the
number of people who adopt the preventive intervention. This
is misleading, because some people who adopt the interven-
tion cannot possibly benefit, for example, a person who takes a
statin and dies in a road traffic accident a month later or
someone who simply stops treatment. Instead of estimating
the benefit to everyone adopting the intervention, it is more
informative to separately estimate the proportion of people
who will benefit, and among them estimate the average years
of life gained without a clinical event the treatment prevents.
If the age-specific incidence rate of serious adverse effects
were known, these could be included in the life table analysis
together with the incidence of myocardial infarction or stroke.
The benefit is then the avoidance of all these outcomes rather
than preventing a myocardial infarction or stroke only. In our
examples, the issue is minor, because there is strong evidence
that salt reduction and the components of the polypill are
almost free from serious adverse effects, with the exception of
the rare occurrence of statin induced rhabdomyolysis. If this
were included as a hazard, neither the percentage of people
who benefit nor the years of life gained would differ at the
level of precision used here, because of the rarity of the
adverse reaction. Current estimates suggest that statin therapy
may increase the risk of clinical diabetes by about 9 % [10].
Our method allows for any increase in the risk of myocardial
infarctions and stroke arising in this way, but not for other
complications of diabetes.
In this paper we consider years of life gained without an
incident myocardial infarction or stroke. The same method
of analysis as that described here could be applied to the
prevention of death from these disorders, in which case the
proportion of people benefitting would be less as not everyone
who has a myocardial infarction or stroke will die from these
disorders, but the years of life gained would be greater due to
the inclusion of years of life after a first clinical event, as well
as years gained before such an event. We selected myocardial
infarction and stroke since they are ‘‘hard’’ end points for
which estimates of incidence are available. Had, for example,
angina been included, the benefits would have been greater.
The approach we propose, which is based on using stan-
dard life-table methods could, to advantage, be readily
adopted, relying on estimates of relative and absolute risk
reductions and data on cause-specific mortality from national
vital statistics. The calculations are straightforward. Life-
table methods are often used in economic cost-benefit anal-
yses, but less so in papers that assess only health benefits.
In summary, the health benefits of preventive interven-
tions are usefully presented in terms of the proportion of
people receiving an intervention who benefit from it and
their average years of life gained. These two measures
overcome the apparent contradictory impressions arising
from reporting estimates of the absolute and relative risk
reduction. In the prevention of chronic disease, where the
biological actions of an intervention exhibit continuous
effects, the two measures of health benefit, calculated using
the holistic model, provide a simple and accurate summary
of the impact of the intervention for individuals and for
populations as a whole.
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Appendix
To assess the health benefits arising from the prevention of
myocardial infarction and stroke through taking a polypill
or through reducing salt intake the following data were
used.
1. The incidence of first myocardial infarction or stroke
in England and Wales in 2010 in people not taking
statins or blood pressure drugs
2. The age specific relative risks of a stroke or myocardial
infarction whilst on the polypill
3. The age-specific relative risks of a stroke or myocar-
dial infarction due to salt reduction
4. The age-specific mortality from all causes other than
myocardial infarctions or strokes in England and
Wales 2010
These are estimated below in the correspondingly
numbered sections.
1. The incidence of first myocardial infarction or stroke
in England and Wales in 2010 in people not taking
statins or blood pressure drugs
To estimate this, we first used published estimates of the
incidence of these disorders in 1985–1995 (section head-
ed ‘‘Annual incidence of first myocardial infarction (MI) and
stroke from 1985–95 [11]’’) and then adjusted them for the
reductions in incidence that occurred between 1995 and 2010
(section headed ‘‘Allowing for the decrease in incidence
from 1985–95 to 2010’’), and then took account of the fact
that about 30 % of people aged 50 and older were taking
statins or blood pressure drugs in 2010 (section
headed ‘‘Allowing for the current use of components of the
polypill in 2010’’).
Annual incidence of first myocardial infarction (MI)
and stroke from 1985 to 1995 [11]
The following unpublished weighted logistic regression equa-
tions from the meta-analysis reported by Law et al. [11] were
used to obtain yearly age specific incidence rates for men:
incidence of first MI = exp(-8.9041 ? 0.06148 9
years)/[1 ? exp(-8.9041 ? 0.06148 9 years)], and
incidence of first stroke = exp(-11.3454 ? 0.08769 9
years)/[1 ? exp(-11.3454 ? 0.08769 9 years)].
For women:
incidence of first MI = exp(-12.5712 ? 0.10332 9
years)/[1 ? exp(-12.5712 ? 0.10332 9 years)], and
incidence of first stroke = exp(-11.8133 ? 0.09112 9
years)/[1 ? exp(-11.8133 ? 0.09112*years)]
Allowing for the decrease in incidence from 1985–95
to 2010
The above incidence estimates relate to 1985–1995. Since
then mortality from myocardial infarction and stroke has
decreased [ONS 1985–1995 [12] versus ONS 2010 [2]; col-
umn 3 in Table 4 (Appendix)] as a result of both a decrease in
incidence and a decrease in case-fatality. Two studies [13, 14]
reported the contributions to the decrease in mortality arising
from a decrease in incidence (I) compared with a decrease in
case fatality (CF) (column 4 in Table 4 (Appendix)). The
decrease in incidence of first MI and strokes from 1985–95 to
2010 (column 5) was estimated using the results of these two
studies and assuming I and CF changed, over time, by the
same proportion (P) (so that the decrease in incidence is P 9 I
and the decrease in case fatality is P 9 CF). Then the decrease
in mortality is 1 – [(1 – P 9 I) (1 – P 9 CF)]. For example
in the second row of Table 4 (Appendix) the decrease in
mortality is 67 %, so 0.67 = 1 – (1 - 0.30P) (1 - 0.43P)
which can be rearranged so that 0.129P2 - 0.73P ?
0.67 = 0. This quadratic equation has two solutions;
P = 1.15 and P = 4.51. P = 4.51 leads to a decrease in
incidence[100 %, which is not possible, so the decrease in
incidence, P 9 I = 1.15 9 30 % = 35 % (as given in col 5).
The age specific incidence of a first myocardial infarc-
tion and stroke in 2010 was estimated by multiplying the
estimated decreases in incidence from 1985–95 to 2010
(column 5 in Table 4 (Appendix)) by the logistic regres-
sion equations for the age specific incidence of a first
myocardial infarction and stroke in 1985–95 given in the
section above headed ‘‘Annual incidence of first myocar-
dial infarction (MI) and stroke from 1985 to 1995’’.
Table 4 Estimation of the decrease in incidence of first myocardial



















Female MI 76 31:29 53
Female Stroke 67 30:43 35
Male MI 69 33:24 51
Male Stroke 64 30:43 33
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Allowing for the current use of components
of the polypill in 2010
Around 30 % of people aged 50–99 were currently taking
blood pressure lowering drugs [15] or statins [16] in 2010.
Therefore the estimated age specific incidence in 2010 at
each age was adjusted by 1/(0.7 ? 0.3 9 age specific
relative risk as given in Table 5 (Appendix)) to estimate
the incidence in people not taking statins or blood pressure
drugs. Details of the estimation of the age specific relative
risks are given below.
2. Estimating the age specific relative risks of a stroke
or myocardial infarction or stroke on the polypill
Table 5 (Appendix) shows the age specific relative risk of
a first myocardial infarction or stroke based on three
sources [4–7]. The age specific relative risk estimates by
single year of age for people aged 50–90 were obtained by
linear interpolation using the relative risks in
Table 5 (Appendix). For people age 90 and above the
relative risks were assumed to be constant.
The relative risk reduction on the polypill taken dai-
ly decreases with age (see Table 5 (Appendix)) and
therefore the average relative risk reduction in people age
50 and over (56 % in Table 6 (Appendix)) is lower than in





a first stroke on
daily polypilla








a Polypill contained amlodipine 2.5 mg, losartan 25 mg, hydrochlo-
rothiazide 12.5 mg and simvastatin 20 mg
Table 6 Average relative risk reductions (%) of a first myocardial




Age starting to take polypill daily
50 60 70 80
10 81 74 64 55
20 75 67 57 51
30 68 59 53 –
40 60 55 – –
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the 50–59 category (81 %), which is similar to the previ-
ously published estimate for a 6 component polypill taken
from age 55 [4].
3. Estimating the age specific relative risks of a first
myocardial infarction or stroke due to salt intake
reduction
Table 7 (Appendix) shows the fall in diastolic blood
pressure and the age specific relative risk of a first myo-
cardial infarction or stroke according to salt intake reduc-
tion based on Ref. [8]. The age specific relative risk
estimates by single year of age for people aged 50–90 were
obtained by linear interpolation using the relative risks in
Table 7 (Appendix). For people age 90 and above the
relative risks were assumed to be constant.
4. Estimating the age-specific mortality from all causes
other than a myocardial infarction or stroke in England
and Wales in 2010
This was obtained from the ONS publication Mortality
Statistics: Deaths Registered in England and Wales (Series
DR), 2010 [17].
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